Why prescription drug prices are plunging
Data: Bureau of Labor Statistics; Chart: Courtenay Brown/Axios America is experiencing its biggest prescription drug price deflation in generations. Why it matters: By one important measure, there is a striking reversal underway for one of health care's most stubbornly expensive necessities amid a major Washington push to lower drug costs. By the numbers: Prescription drug prices fell 0.8% in…
Prescription drug prices in the United States have been experiencing a significant decline, marking the largest such drop in generations. This trend has been driven by a confluence of factors, most notably the implementation of measures under the Inflation Reduction Act (IRA) and strategic actions by the Trump administration. Over the past year, prescription drug prices have fallen by 3.1%, the steepest annual decrease in over six decades, as reported by the Consumer Price Index.
Notably, there hasn't been a price increase in any month this year, indicating a persistent pattern of declining costs.
The Bureau of Labor Statistics attributes this reduction in part to Medicare negotiations under the IRA, which have brought prices for 10 of the most expensive Medicare drugs down by up to 79% below their list prices. Additionally, the administration's TrumpRx initiative, which connects patients with discounted cash prices for certain drugs, has likely played a role though it is likely not the primary driver.
Eli Lilly and Novo Nordisk, in particular, have negotiated reduced cash prices for their blockbuster GLP-1 drugs, potentially contributing to broader downward pressure on drug prices. These price cuts may be partly due to market forces, such as the entry of cheaper generic drugs into the market following the expiration of patents on blockbuster drugs.
Written by urgent.news from Axios's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
